Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Non Operating Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Non Operating Income data on record, last reported at $4.9 million in Q1 2026.

  • On a quarterly basis, Non Operating Income rose 9.21% to $4.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $16.7 million, a 19.86% increase, with the full-year FY2025 number at $16.2 million, up 27.09% from a year prior.
  • Non Operating Income reached $4.9 million in Q1 2026 per OLMA's latest filing, up from $4.0 million in the prior quarter.
  • Over the last five years, Non Operating Income for OLMA hit a ceiling of $4.9 million in Q1 2026 and a floor of $224000.0 in Q1 2022.
  • A 5-year average of $2.6 million and a median of $3.1 million in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 924.49% in 2022, then decreased 12.16% in 2024.
  • Tracing OLMA's Non Operating Income over 5 years: stood at $1.0 million in 2022, then skyrocketed by 250.38% to $3.6 million in 2023, then fell by 12.16% to $3.2 million in 2024, then grew by 25.68% to $4.0 million in 2025, then increased by 21.73% to $4.9 million in 2026.
  • Business Quant data shows Non Operating Income for OLMA at $4.9 million in Q1 2026, $4.0 million in Q4 2025, and $3.7 million in Q3 2025.